PR
For a better future SCM Lifescience will do its best
[ESG] Signed 'Joint Business Agreement for Strategic Technology Commercialization' between Inha University, Inha University Hospital, and SCM Lifescience, Inc.
Notice
2022-11-15

Dear shareholders, 


SCM Lifescience, Inc.'s beginning is the ‘Inha University Hospital Adult Stem Cell Project Group', which was created through the 'Inha University School of Medicine Laboratory Startup Process'. Through activities in the project group, our company published the ‘Subfractionation Culturing Method’, the source technology for stem cell separation and culture, proved the stem cell treatment mechanism, and achieved the achievement of listing on the KOSDAQ as the No. 1 technology commercialization company in Inha University Hospital.


SCM Lifescience, Inc. did not come to this point on its own.

Based on the root of 'Trust', each organization supported each other so that they did not fall, and cooperated, so we were able to grow into a giant tree that does not fall even in the face of trials.


Now, we want to create a new redwood forest by winding the roots of trust with each institution more tightly.


The main contents of the agreement are as follows.


▲ Establish a cooperative system to foster technology commercialization and commercialize research results


▲ Discover promising technologies in the biomedical business field and operate a technology commercialization support program

▲ Sharing of medical and clinical information necessary for basic research, translational research, clinical trials, and research


▲ Human resources and academic (technical) exchange, information exchange, and joint use of equipment


▲ Joint research planning and national project execution


▲ Cooperation to promote technology commercialization



Through the 'Joint Business Agreement for Strategic Technology Commercialization' between Inha University, Inha University Hospital, and SCM Lifescience, Inc.

We intend to create a research platform foundation for the industry, academia, research institutes, hospitals, and government agencies to increase the speed and quality of bio-convergence research outcomes. SCM Lifescience, Inc. is in charge of investment in this, and we would like to share the company’s ‘incubating program’ and ‘acceleration’ capabilities so that excellent research results can be commercialized early.


Like a redwood forest where giant trees support each other with their long-stretched roots and share nutrients, with the spirit of 'trust' and 'cooperation', we will work together to become the cornerstone of the development of the bio industry in the local community, create social public interest, and lead the medical industry.